

66-
This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

LAW OFFICES
WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP

A PARTNERSHIP INCLUDING PROFESSIONAL CORPORATIONS

**ONE LIBERTY PLACE - 46TH FLOOR
PHILADELPHIA, PA 19103-7301**

(215) 568-3100

Facsimile: (215) 568-3439

DATE: February 8, 2001

JOB CODE: 52390

Please deliver this and the following pages to:

Name: Dianne E. Maggard

Company/Firm: USPTO BOPAI

Telecopier No.: 703 308 6200

Client/Matter No.: ISIS 4502

SENDER'S NAME: John W. Caldwell

PAGES TO FOLLOW: 7

If transmission is not complete, please call (215) 568-3100

COVER MESSAGE:

Ms. Maggard: As per our conversation of today.

BOARD OF PATENT
APPEALS &
INTERFERENCES
FEB 13 2001

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE FOR DELIVERY OF THE MESSAGE TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE AND RETURN THE ORIGINAL TO US AT THE ABOVE ADDRESS VIA THE U.S. POSTAL SERVICE. THANK YOU

DOCKET NO.: ISIS-4502

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Richard H. Tullis

Serial No.: 08/078,768

Filing Date: June 16, 1993

For: Oligonucleotide Therapeutic Agents and Methods of Making Same

BOARD OF PATENT
APPEALS &
INTERFERENCES
FEB 13 2001

DATE OF DEPOSIT: _____
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS ADDRESSED
TO THE BOARD OF PATENT APPEALS AND
INTERFERENCES COMMISSIONER OF PATENTS AND
TRADEMARKS, WASHINGTON, DC 20231.

TYPED NAME: John W Caldwell
REGISTRATION NO

Board of Patent Appeals and Interferences
Commissioner of Patents and Trademarks
Washington DC 20231

STATEMENT UNDER 37 C.F.R. §3.73(b)

Molecular Biosystems, Inc., a corporation, states that it is:

- ☒ the assignee of the entire right, title, and interest; or
☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above.
☒ 1. The assignment was recorded in the Patent and Trademark Office at Reel 3941, Frame 0775. The assignment was again recorded in the Patent and Trademark Office at Reel 4079, Frame 0445 due to a name change of the assignee.

DOCKET NO.: ISIS-4502

- 2 -

PATENT

☐ 2. The assignment has not yet been recorded. A copy of the assignment is attached.

OR

OR
B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

i. From _____ To: _____ The document was recorded in the Patent and Trademark Office at Reel _____, Frame(s) _____, or for which a copy thereof is attached. _____ The document was recorded in _____

ii. From: _____ To: _____ The document was recorded in the Parent and Trademark Office at Reel _____, Frame(s) _____, or for which a copy thereof is attached. _____

iii. From: _____ To: _____ The document was recorded in the Patent and Trademark Office at Reel _____, Frame(s) _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.


Signature

Name: Lloyd A. Rowland

Title: Vice President's General Counsel

Date: Feb. 7, 2001

DOCKET NO.: ISIS-4502

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BOARD OF PATENT APPEALS
AND INTERFERENCES

In reAppeal of:

Examiner: J. Martinell

Richard H. Tullis

Art Unit: 1804

Appeal No. 1998 - 0218

Serial No. 08/078,768

Filed: June 16, 1993

For: Oligonucleotide Therapeutic Agent and Methods of Making Same

I, John W. Caldwell, Registration No. 28,937 certify that this correspondence is being
facsimile transmitted to the USPTO to the attention of Diane Maggard at 703 308
6200 on February 8, 2001.

John W. Caldwell
John W. Caldwell, Registration No. 28,937

BOARD OF PATENT
APPEALS &
INTERFERENCES
FEB 13 2001

REQUEST FOR SUSPENSION OF APPEAL
IN ORDER TO SUBMIT MATERIALS FOR
CONSIDERATION BY THE EXAMINER

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

This appeal is presently scheduled for hearing on February 20, 2001 in accordance with the Notice of Hearing appended hereto. Effective ownership of this application has recently changed and a new Power of Attorney in favor of the undersigned, copy attached, has just been executed. It is requested that the hearing be postponed and the application be redirected to the Examiner for further proceedings.

In particular, applicant wishes to inform the Patent Office of the issuance of U.S. Patent 5,919,619, issued from a continuation application to the present application filed May 31, 1995. In that patent prosecution, the Examiner and applicant reached agreement as to thirteen claims. Except for a single limitation, claim 1 of the 619 patent is identical to claim 1 now on appeal. Claim 1 of

DOCKET NO.: ISIS-4502**PATENT**

the 619 Patent is limited to methods of downregulated protein by antisense oligonucleotides in cell cultures, while the claims on appeal do not have the cell culture limitation. The Examiner's consideration of this issue will doubtless lead to simplification and possibly elimination of the issues before the board. This is because many of the objective bases for the extant §112 rejection are applicable to uses of the invention under both *in vivo* and *in vitro* conditions. Consistency of examination requires reconsideration by the Examiner. A fuller discussion of the points and authorities appertaining to this issue will be submitted following remand.

Applicants also wish the Examiner to be aware of an unfavorable ruling by the European Patent Office with regard to a related application before that body. Again, fuller information will be supplied to the Examiner.

Accordingly, it is requested that this Appeal be suspended pending further review by the Examiner. A time period of ninety days should be set for further submissions by Applicant.

Respectfully submitted

Date:

February 8, 2001

John W. Caldwell

Registration No. 28,937

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100



UNITED STATES DEPARTMENT OF
COMMERCE
Patent and Trademark
ASSISTANT SECRETARY AND COMMISSIONER OF
PATENTS AND TRADEMARKS
Washington, D.C. 20231

250

Townsend, Townsend,
Khouri & Crew
~~Markel~~
Steven Street Tower 20th Floor
San Francisco, CA 94105

Appeal No:
Appellant:
Application No:
Hearing Room:
Hearing Docket:
Hearing Date:
Hearing Time:
Location:

Paper No. 57

1998-0218
Richard H. Tullis
08/078,768
[REDACTED]
[REDACTED]
Tuesday, February 20, 2001
9:00 AM
Room 12C07
CRYSTAL GATEWAY 2
1225 Jefferson Davis Highway
Arlington, VA 22202

NOTICE OF HEARING**CONFIRMATION REQUIRED WITHIN TWENTY-ONE DAYS**

Your attention is directed to 37 CFR § 1.194(a).

The above identified appeal will be heard by the Board of Patent Appeals and Interferences on the date indicated. Hearings will commence at the time set and as soon as the argument in one appeal is concluded, the succeeding appeal will be taken up.

The time allowed for argument is twenty minutes unless additional time is requested and permitted before the argument is commenced.

CONFIRMATION OR WAIVER OF THE HEARING IS REQUIRED.

This form must be completed below and filed with the Board of Patent Appeals and Interferences preferably by facsimile within TWENTY-ONE (21) DAYS from the mailing date of this notice indicating confirmation or waiver of the hearing. A copy of this form may alternatively be filed by mail if facsimile is not available.

Failure to file this form within this time period will be construed as a waiver of the request for oral hearing.

37 CFR § 1.136(a) does not apply.

By order of the Board of Patent Appeals and Interferences

BPAI FAX No:

(703)-308-6200

1108 Off. Gaz. Pat. Trademark
Office 15 (Nov. 14, 1989).

Paralegal Specialist
Dianne E. Maggard
(703)-305-4673

BPAI Mailing Address:

See BOARD OF PATENT APPEALS AND INTERFERENCES
COMMISSIONER OF PATENTS AND TRADEMARKS
WASHINGTON, D.C. 20231

MAILED

In all communications relating to this appeal, please identify the appeal by its number.

OCT - 6 2000

CHECK ONE:

☒ HEARING ATTENDANCE CONFIRMED
☐ HEARING ATTENDANCE WAIVED

PAT. & T.M. OFFICE
BOARD OF PATENT APPEALS
AND INTERFERENCES

Kent A. Weber
Signature of Attorney/Agent/Appellant
Kenneth A. Weber

Date

11/6/00

Registration No 31,677